Best Penny Stocks Under $1.00 Right Now

The stock market has had an incredible bull-run since the Great Recession of 2008 and 2009. While stocks are no longer hitting new all-time highs, the price-to-earnings ratios of most S&P 500 companies still look somewhat expensive historically speaking. Many investors are having trouble finding low-priced stocks that have great business fundamentals and actually generate cash flow.

Stocks have gotten expensive both in-terms of share price and their valuation relative to earnings. In more normal markets, a typical S&P 500 company has traded at about fifteen times their earnings. Most stocks are currently trading closer to 20 times their annual earnings. While the stock market is more expensive as a whole than it has been historically, there are still a handful of undervalued stocks that are trading at less than $1.00 per share.

Value investing opportunities do exist if you're looking in the right places. Putting together a list of the best stocks under $1.00 requires investors to look at smaller and riskier companies and in sectors that are either undiscovered or unloved by the market as a whole. Some of these cheap stocks may not look especially attractive today, but long-term investors will profit if they are willing to exercise patience and hold on to shares of these comapnies through multiple economic cycles.

Some of these companies are solid investing ideas because they are too little and considered too risky to attract the interest of most managed mutual funds and Wall Street money managers. Others operate in unloved and untested areas of the market. You may find even find crypto stocks, marijuana stocks, and biotechnology stocks on this list. Others have been beat up by Mr. Market after a long period of slowing profits, but are now actively trying to turn around their business and bounce back. These low-priced stocks operate in a lot of different industries, but these picks all carry two common characteristics. They all have a super-low share price of $1.00 (1 dollar) or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts.

#1 - Lucid Diagnostics

NASDAQ:LUCD

Stock Price:

$0.87 (+$0.03)

P/E Ratio:

-0.68

Market Cap:

$45.60 million

Average Trading Volume:

165,233 shares

Consensus Rating:

Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$4.00 (359.8% Upside)

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

#2 - Unicycive Therapeutics

NASDAQ:UNCY

Stock Price:

$0.38 (-$0.02)

P/E Ratio:

-0.32

Market Cap:

$14.14 million

Average Trading Volume:

1.06 million shares

Consensus Rating:

Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$5.13 (1,263.0% Upside)

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

#3 - Cue Biopharma

NASDAQ:CUE

Stock Price:

$0.91 (+$0.04)

P/E Ratio:

-0.85

Market Cap:

$44.03 million

Average Trading Volume:

351,236 shares

Consensus Rating:

Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$5.00 (452.4% Upside)

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

#4 - Vor Biopharma

NYSE:VOR

Stock Price:

$1.00 (+$0.01)

P/E Ratio:

-0.56

Market Cap:

$68.15 million

Average Trading Volume:

308,017 shares

Consensus Rating:

Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$10.92 (995.6% Upside)

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

#5 - Wag! Group

NASDAQ:PET

Stock Price:

$0.71 (-$0.06)

P/E Ratio:

-1.98

Market Cap:

$29.02 million

Average Trading Volume:

107,950 shares

Consensus Rating:

Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$4.40 (515.8% Upside)

Wag! Group Co. develops and supports a proprietary marketplace technology platform available as a website and mobile app that enables independent pet caregivers to connect with pet parents. Its platform allows pet parents, who require specific pet care services, such as dog walking, pet sitting and boarding, advice from licensed pet experts, home visits, training, and pet insurance comparison tools. The company was founded in 2014 and is headquartered in San Francisco, California.

#6 - Aptose Biosciences

NASDAQ:APTO

Stock Price:

$0.46 (-$0.02)

P/E Ratio:

-0.07

Market Cap:

$8.36 million

Average Trading Volume:

82,052 shares

Consensus Rating:

Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$14.80 (3,104.9% Upside)

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

#7 - Gossamer Bio

NASDAQ:GOSS

Stock Price:

$0.94 (+$0.01)

P/E Ratio:

-0.89

Market Cap:

$212.65 million

Average Trading Volume:

1.65 million shares

Consensus Rating:

Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$9.20 (878.7% Upside)

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

#8 - Dragonfly Energy

NASDAQ:DFLI

Stock Price:

$0.61 (+$0.02)

P/E Ratio:

-1.12

Market Cap:

$37.02 million

Average Trading Volume:

673,857 shares

Consensus Rating:

Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$1.79 (195.7% Upside)

Dragonfly Energy Holdings Corp. engages in the manufacturing and sale of deep cycle lithium-ion batteries for recreational vehicles, marine vessels, solar and off-grid residence industries, and industrial and energy storage markets. The company provides lithium power systems comprising solar panels, chargers and inverters, system monitoring, alternator regulators, accessories, and others. It also offers battery management systems for monitoring and controlling of battery systems and to protect battery cells from damage in various scenarios. The company provides its products under the Dragonfly Energy, Battle Born, and Wakespeed brand names. Dragonfly Energy Holdings Corp. is headquartered in Reno, Nevada.

#9 - Elevation Oncology

NASDAQ:ELEV

Stock Price:

$0.81

P/E Ratio:

-0.78

Market Cap:

$44.28 million

Average Trading Volume:

1.87 million shares

Consensus Rating:

Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$7.80 (862.5% Upside)

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.

#10 - Beyond Air

NASDAQ:XAIR

Stock Price:

$0.46 (-$0.04)

P/E Ratio:

-0.25

Market Cap:

$21.23 million

Average Trading Volume:

531,846 shares

Consensus Rating:

Buy (4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$3.67 (692.8% Upside)

Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.

#11 - Karyopharm Therapeutics

NASDAQ:KPTI

Stock Price:

$0.81 (+$0.02)

P/E Ratio:

-0.64

Market Cap:

$100.85 million

Average Trading Volume:

1.44 million shares

Consensus Rating:

Moderate Buy (4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$4.80 (493.1% Upside)

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

#12 - Reviva Pharmaceuticals

NASDAQ:RVPH

Stock Price:

$0.85 (-$0.29)

P/E Ratio:

-0.53

Market Cap:

$25.28 million

Average Trading Volume:

356,361 shares

Consensus Rating:

Moderate Buy (4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$14.33 (1,591.0% Upside)

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.

#13 - ESS Tech

NYSE:GWH

Stock Price:

$0.57 (+$0.02)

P/E Ratio:

-1.26

Market Cap:

$99.32 million

Average Trading Volume:

885,024 shares

Consensus Rating:

Moderate Buy (4 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$1.74 (206.9% Upside)

ESS Tech, Inc., an energy storage company, designs and produces iron flow batteries for commercial and utility-scale energy storage applications worldwide. It offers energy storage products, which include Energy Warehouse, a behind-the-meter solution; and Energy Center, a front-of-the-meter solution. The company was founded in 2011 and is headquartered in Wilsonville, Oregon.

#14 - Cognition Therapeutics

NASDAQ:CGTX

Stock Price:

$0.75 (-$0.02)

P/E Ratio:

-0.82

Market Cap:

$30.04 million

Average Trading Volume:

478,548 shares

Consensus Rating:

Moderate Buy (4 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$8.00 (967.0% Upside)

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

#15 - Oatly Group

NASDAQ:OTLY

Stock Price:

$0.91 (-$0.02)

P/E Ratio:

-1.13

Market Cap:

$539.07 million

Average Trading Volume:

1.79 million shares

Consensus Rating:

Moderate Buy (4 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$1.96 (116.4% Upside)

Oatly Group AB, an oatmilk company, provides a range of plant-based dairy products made from oats in Europe, the Middle East, Africa, the Americas, and Asia. It offers Barista edition oatmilk, oatgurts, frozen desserts, ice-creams, and yogurts; cooking products, including cooking cream, in regular and organic, Crème Fraiche, whipping cream, vanilla custard, and spreads in a variety of flavors; and ready-to-go drinks. The company was formerly known as Havre Global AB and changed its name to Oatly Group AB in March 2021. Oatly Group AB was founded in 1994 and is headquartered in Malmö, Sweden.

#16 - ThredUp

NASDAQ:TDUP

Stock Price:

$0.79 (+$0.05)

P/E Ratio:

-1.24

Market Cap:

$87.19 million

Average Trading Volume:

628,430 shares

Consensus Rating:

Moderate Buy (4 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$3.33 (321.5% Upside)

ThredUp Inc., together with its subsidiaries, operates an online resale platform in the United States and internationally. Its platform enables consumers to buy and sell primarily secondhand apparel, shoes, and accessories. ThredUp Inc. was incorporated in 2009 and is headquartered in Oakland, California.

#17 - Innoviz Technologies

NASDAQ:INVZ

Stock Price:

$0.72 (-$0.03)

P/E Ratio:

-0.94

Market Cap:

$98.05 million

Average Trading Volume:

2.32 million shares

Consensus Rating:

Moderate Buy (3 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$3.85 (434.7% Upside)

Innoviz Technologies Ltd. manufactures and sells automotive grade LiDAR sensors and perception software to enable safe autonomous driving at a mass scale. The company offers InnovizOne, a solid-state LiDAR sensor designed for automakers and robotaxis, shuttles, trucks, and delivery companies requiring an automotive-grade and mass-producible solution to achieve autonomy. It also provides InnovizTwo, an automotive-grade LiDAR sensor that offers a solution for all levels of autonomous driving, as well as an option to integrate the perception application in the LiDAR sensor; and perception application, a software application that raw point cloud data from Innoviz LiDAR products into perception outputs. The company operates in Europe, Asia Pacific, the Middle East, Africa, and North America. It markets and sells its products through a direct sales organization, as well as through distribution channels. The company is headquartered in Rosh Haayin, Israel.

#18 - FTC Solar

NASDAQ:FTCI

Stock Price:

$0.27 (-$0.01)

P/E Ratio:

-0.69

Market Cap:

$33.68 million

Average Trading Volume:

751,825 shares

Consensus Rating:

Moderate Buy (3 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$1.11 (313.0% Upside)

FTC Solar, Inc. engages in the provision of solar tracker systems, software, and engineering services in the United States, Asia, Europe, the Middle East, North Africa, South Africa, and Australia. The company offers a self-powered, two-panel in-portrait, and single-axis tracker solution under the Voyager brand name; and a one module-in-portrait solar tracker solution under the Pioneer brand name. Its customers include project developers and solar asset owners, as well as engineering, procurement, and construction contractors that design and build solar energy projects. The company was incorporated in 2017 and is headquartered in Austin, Texas.

#19 - BioXcel Therapeutics

NASDAQ:BTAI

Stock Price:

$0.68 (+$0.01)

P/E Ratio:

-0.13

Market Cap:

$25.54 million

Average Trading Volume:

954,200 shares

Consensus Rating:

Moderate Buy (3 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$5.50 (708.2% Upside)

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.

#20 - Outset Medical

NASDAQ:OM

Stock Price:

$0.69 (+$0.10)

P/E Ratio:

-0.20

Market Cap:

$35.69 million

Average Trading Volume:

1.42 million shares

Consensus Rating:

Hold (4 Buy Ratings, 2 Hold Ratings, 1 Sell Ratings)

Consensus Price Target:

$4.64 (572.9% Upside)

Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also provides Tablo Data Ecosystem, including TabloHub, a customer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.

#21 - Lion Electric

NYSE:LEV

Stock Price:

$0.68

P/E Ratio:

-1.39

Market Cap:

$154.26 million

Average Trading Volume:

464,222 shares

Consensus Rating:

Hold (2 Buy Ratings, 7 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$1.52 (123.1% Upside)

The Lion Electric Company designs, develops, manufactures, and distributes purpose-built all-electric medium and heavy-duty urban vehicles in North America. The company's products include battery systems, chassis, bus bodies, and truck cabins. It distributes truck and bus parts, as well as accessories. The company was incorporated in 2008 and is based in Saint-Jérôme, Canada.

#22 - Spruce Biosciences

NASDAQ:SPRB

Stock Price:

$0.48 (+$0.02)

P/E Ratio:

-0.42

Market Cap:

$19.75 million

Average Trading Volume:

798,051 shares

Consensus Rating:

Hold (2 Buy Ratings, 6 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$5.00 (945.6% Upside)

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

#23 - bluebird bio

NASDAQ:BLUE

Stock Price:

$0.72 (+$0.06)

P/E Ratio:

-0.97

Market Cap:

$78.43 million

Average Trading Volume:

7.78 million shares

Consensus Rating:

Hold (4 Buy Ratings, 7 Hold Ratings, 1 Sell Ratings)

Consensus Price Target:

$4.74 (561.4% Upside)

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

#24 - Allakos

NASDAQ:ALLK

Stock Price:

$0.75 (+$0.04)

P/E Ratio:

-0.31

Market Cap:

$66.18 million

Average Trading Volume:

904,267 shares

Consensus Rating:

Hold (2 Buy Ratings, 2 Hold Ratings, 1 Sell Ratings)

Consensus Price Target:

$1.67 (123.0% Upside)

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.

#25 - Stem

NYSE:STEM

Stock Price:

$0.63 (+$0.06)

P/E Ratio:

-0.43

Market Cap:

$102.49 million

Average Trading Volume:

4.97 million shares

Consensus Rating:

Hold (2 Buy Ratings, 10 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$2.71 (329.9% Upside)

Stem, Inc. operates as a digitally connected, intelligent, and renewable energy storage network provider worldwide. The company offers energy storage hardware sourced from original equipment manufacturers (OEMs); edge hardware to aid in the collection of site data and real-time operation and control of the site and other optional equipment; and Athena, a software platform, which offers battery hardware and software-enabled services to operate the energy storage systems. It serves commercial and industrial enterprises, independent power producers, renewable project developers, and utilities and grid operators. The company was incorporated in 2009 and is headquartered in San Francisco, California.

More Stock Ideas from MarketBeat

Sign in to your free account to enjoy these benefits

• In-depth profiles and analysis for 20,000 public companies.
• Real-time analyst ratings, insider transactions, earnings data, and more.
• Our daily ratings and market update email newsletter.

Sign in to your free account to enjoy all that MarketBeat has to offer.

• Sign In
• Create Account

Your Email Address:

Your Password:

Log In

---

or

Sign in with Facebook Sign in with Google

Forgot your password?

Your Email Address:

Choose a Password:

Create My Account (Free)

---

or

Sign in with Facebook Sign in with Google

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.